AJMC links anti‑VEGF outcomes to access

AJMC published a review on May 21 that said anti-VEGF medicines remain the foundation of care for retinal vascular diseases, even as outcomes in routine practice often fall short of clinical-trial results. The article covered neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion, and said the main gap is not whether the drugs work pharmacologically but whether patients can stay on treatment. It said durability, treatment burden and long-term disease management remain unresolved in day-to-day retina care. ### If the drugs work, why do clinic results still disappoint? AJMC’s panel said anti-VEGF therapies have “significantly transformed the treatment landscape” over two decades by preserving vision and improving long-term outcomes for patients who once faced progressive vision loss and blindness. The review said those gains are harder to reproduce outside tightly managed trials because routine care depends on repeated injections, office visits and sustained follow-up. (ajmc.com) A 2026 Clinical Ophthalmology review by Jay Umed Sheth described the same pressure points in broader terms, saying treatment burden, variable response and cost continue to limit real-world outcomes. That framing aligns with AJMC’s account that weaker results in practice are often linked to access and adherence rather than a loss of anti-VEGF effect itself. (ajmc.com) ### Which patients are most exposed to the access problem? AJMC said the issue runs across the main retinal vascular diseases treated with anti-VEGF injections, including wet AMD, DME, DR and RVO. In each of those conditions, the article said, clinicians are balancing efficacy against the need for sustained disease control over months and years. Retina specialists and reviewers have increasingly focused on patients who miss visits, stretch injection intervals unintentionally or stop treatment because of logistics and cumulative burden. (dovepress.com) The International Journal of Ophthalmology and Vision Science perspective in IOVS said maintaining therapeutic outcomes remains a real-world challenge even after anti-VEGF agents revolutionized care. (ajmc.com) ### What exactly is creating the treatment burden? AJMC said durability and dosing frequency remain central obstacles because many patients need repeated intravitreal injections and repeated monitoring visits. The article said clinicians are looking for therapies that can maintain visual outcomes while reducing the frequency of injections and office appointments. (iovs.arvojournals.org) Nature’s Eye review, published May 21, said intravitreal anti-VEGF therapies are the standard of care for diseases such as neovascular AMD and diabetic macular edema, underscoring how dependent current practice still is on repeated office-based delivery. That helps explain why missed follow-up, transport difficulties, treatment fatigue and cost can have as much effect on vision outcomes as molecule choice in a busy clinic. That final point is an inference drawn from the treatment model described in the sources. (ajmc.com) ### Are newer drugs supposed to solve this, or just stretch the interval? AJMC said the field is moving toward more durable anti-VEGF therapies aimed at improving adherence and optimizing real-world outcomes. The review did not present a new trial, but it pointed to the next generation of therapies as part of an effort to reduce visit burden while preserving visual function and independence. (nature.com) Retinal Physician reported in April that newer agents such as aflibercept 8 mg and faricimab are designed to extend dosing intervals, while other biologics and gene therapies are being studied for neovascular AMD. Those programs are being watched largely for whether they can reduce injection frequency in practice, not only for anatomical drying or trial efficacy. (ajmc.com) ### What should readers watch for next? AJMC said the next episode in its series, titled “Role of Anti-VEGF Real-World Evidence in Retinal Vascular Diseases,” will focus on how treatment patterns and durability in routine practice compare with trial outcomes. The panel said that discussion will cover adherence, dosing frequency and patient variability in long-term care. (retinalphysician.com) May 2026 reporting and reviews across AJMC, Clinical Ophthalmology and Retinal Physician all point to the same next checkpoint: whether newer anti-VEGF approaches can cut the number of visits and injections patients must complete to keep vision stable in ordinary clinics. (ajmc.com)